天士力(600535.SH):天士營銷1月3日起終止新三板掛牌
格隆匯1月3日丨天士力(600535.SH)公佈,天津天士力醫藥營銷集團股份有限公司(“天士營銷”)為公司持股87.47%的控股子公司。根據天士營銷發展規劃及整體戰略需要,公司於2019年10月16日召開第七屆董事會第11次會議審議通過了《關於控股子公司申請從全國中小企業股份轉讓系統摘牌的議案》,同意天士營銷向全國中小企業股份轉讓系統申請公司股票終止掛牌。
近日,天士營銷收到全國中小企業股份轉讓系統有限責任公司出具的《關於天津天士力醫藥營銷集團股份有限公司股票終止掛牌的公告》(股轉系統公告[2019]1833號),天士營銷股票自2020年1月3日起終止在全國中小企業股份轉讓系統掛牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.